X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
USP
0
JP
0
Other Listed Suppliers
0
0
1. 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine
2. Be 5895
3. Be-5895
4. Cynt
5. Moxon
6. Moxonidin
7. Normatens
8. Physiotens
1. 75438-57-2
2. Norcynt
3. Nucynt
4. 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
5. Cynt
6. Be 5895
7. 4-chloro-n-imidazolidin-2-ylidene-6-methoxy-2-methylpyrimidin-5-amine
8. Bdf5895
9. Bdf 5895
10. Lomox
11. Be-5895
12. 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine
13. Ly 326869
14. Bdf5896
15. Be5895
16. Cc6x0l40gw
17. Ly326869
18. 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-
19. Chembl19236
20. Chebi:7009
21. 4-chloro-5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine
22. 75438-57-2 (free Base)
23. Bdf-5896
24. Ncgc00015649-02
25. Normoxocin
26. Ly-326869
27. Cas-75438-57-2
28. 4-chloro-5-(2-imidazolidinyldeneamino)-6-methoxy-2-methylpyrimidine
29. Dsstox_cid_25170
30. Dsstox_rid_80720
31. Dsstox_gsid_45170
32. Moxonidinum [latin]
33. Moxonidina [spanish]
34. Moxonidina
35. Moxonidinum
36. 4-chloro-n-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine
37. Moxonidine Hydrochloride Hydrate
38. Moxonidine [inn]
39. Bdf-5895
40. Unii-cc6x0l40gw
41. Moxonidine [usan:inn:ban]
42. N-(4-chloro-6-methoxy-2-methylpyrimidin-5-yl)imidazolidin-2-imine
43. Sr-01000075981
44. Cynt (tn)
45. Moxonidine [mi]
46. Moxonidine (usan/inn)
47. Prestwick0_001016
48. Prestwick1_001016
49. Prestwick2_001016
50. Prestwick3_001016
51. Lopac-m-1559
52. Moxonidine [usan]
53. Monoxidine [common Misspelling Of Moxonidine]
54. Moxonidine [mart.]
55. Moxonidine [who-dd]
56. Lopac0_000753
57. Schembl49143
58. Bspbio_001171
59. Mls002222183
60. Spbio_003042
61. Bpbio1_001289
62. Dtxsid5045170
63. Moxonidine [ep Monograph]
64. Hms1571k13
65. Hms2098k13
66. Hms2230b15
67. Hms3373o04
68. Hms3655b17
69. Hms3715k13
70. Hms3747a03
71. Moxonidine 1.0 Mg/ml In Methanol
72. Albb-022451
73. Bcp23003
74. Ex-a3409
75. Hy-b0374
76. Zinc1854466
77. Tox21_110190
78. 2-(6-chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline
79. 4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine
80. Ac-637
81. Bdbm50050093
82. Mfcd22689455
83. Pdsp1_000177
84. Pdsp2_000176
85. S2066
86. Stl419983
87. Stl450991
88. Akos015895873
89. Akos015997932
90. Tox21_110190_1
91. Af-0062
92. Ccg-204838
93. Db09242
94. Sdccgsbi-0050731.p002
95. Ncgc00015649-01
96. Ncgc00015649-04
97. Ncgc00015649-05
98. Ncgc00015649-08
99. Ncgc00015649-17
100. Ncgc00092355-02
101. Smr000857402
102. Ab00514003
103. Ft-0601601
104. Ft-0657360
105. M2660
106. Sw196502-4
107. C07451
108. D05087
109. Ab00514003-08
110. Ab00514003_10
111. 438m572
112. A838414
113. Q419944
114. Sr-01000075981-7
115. Brd-k77771411-001-04-4
116. (4-chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine
117. 4-chloro-n-(imidazolin-2-ylidene)-6-methoxy-2-methyl-5-pyrimidinamine
118. 5-pyrimidinamine, 4-chloro-n-2-imidazolidinylidene-6-methoxy-2-methyl-
119. Bdf5895;bdf-5895;bdf 5895;be 5895; Be-5895; Be5895
120. 2-(4-chloro-6-methoxy-2-methyl-pyrimidin-5-ylamino)-4,5-dihydro-3h-imidazol-1-ium
121. 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci)
122. (2r,4r)-1-[(2s)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- Quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic Acid
123. 1008754-16-2
124. 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-pyrimidin-5-amine Hydrochloride;moxonidine
| Molecular Weight | 241.68 g/mol |
|---|---|
| Molecular Formula | C9H12ClN5O |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 241.0730377 g/mol |
| Monoisotopic Mass | 241.0730377 g/mol |
| Topological Polar Surface Area | 71.4 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 275 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of mild to moderate essential or primary hypertension. Effective as most first-line antihypertensives when used as monotherapy.
FDA Label
Treatment of hypertension
Antihypertensive agent whose site of action is the Central Nervous System (CNS), specifically involving interactions with I1- imidazoline and alpha-2-adrenergic rececptors within the rostral ventrolateral medulla (RSV).
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C02AC05
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C02 - Antihypertensives
C02A - Antiadrenergic agents, centrally acting
C02AC - Imidazoline receptor agonists
C02AC05 - Moxonidine
Absorption
90% of an oral dose is absorbed with negligible interference from food intake or first pass metabolism, resulting in a high bioavailability of 88%.
Route of Elimination
Elimination is nearly entirely via the kidneys with a majority (50 -75%) of overall moxonidine being eliminated unchanged through renal excretion. Ultimately, more than 90% of a dose is eliminated by way of the kidneys within the first 24 hours after administration, with only approximately 1% being eliminiated via faeces.
Volume of Distribution
1.80.4L/kg.
Clearance
Administered twice daily due to short half life. However, lower dosage adjustments and close monitoring is necessary in elderly and renal impairment patients due to reduced clearance. In particular, the exposure AUC can increase by about 50% following a single dose and at steady state in elderly patients and moderately impaired renal function with GFR between 30-60 mL/min can cause AUC increases by 85% and decreases in clearence to 52 %.
Biotransformation is unimportant with 10-20% of moxonidine undergoing oxidation reactions to the primary 4,5-dehydromoxonidine metabolite and a guanidine derivative by opening of the imidazoline ring. The antihypertensive effects of these 4,5-dehydromoxonidine and guanidine metabolites are only 1/10 and 1/100 the effect of moxonidine. Oxidation on either the methyl group (pyrimidine ring) or on the imidazole ring of moxonidine results in the formation of the hydroxylmethyl moxonidine metabolite or the hydroxy moxonidine metabolite. The hydroxy moxonidine metabolite can be further oxidized to the dihydroxy metabolite or it can lose water to form the dehydrogenated moxonidine metabolite, which itself can be further oxidized to form an N-oxide. Aside from these Phase I metabolites, Phase II metabolism of moxonidine is also evident with the presence of a cysteine conjugate metabolite minus chlorine. Nevertheless, the identification of the hydroxy moxonidine metabolite with a high level of dehydrogenated moxonidine metabolite in human urine samples suggests that dehydrogenation from the hydroxy metabolite to the dehydrogenated moxonidine metabolite represents the primary metabolic pathway in humans. The cytochromes P450 responsible for the metabolism of moxonidine in humans have not yet been determined. Ultimately, the parent moxonidine compound was observed to be the most abundant component in different biological matrices of urinary excretion samples, verifying that metabolism only plays a modest role in the clearance of moxonidine in humans.
Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours.
Stimulation of central alpha 2-adrenergic receptors is associated with sympathoadrenal suppression and subsequent reduction of blood pressure. As this class was further explored it was discovered that sympathoadrenal activity can also be suppressed by a second pathway with a newly discovered drug target specific to imidazolines. Specifically, moxonidine binds the imidazoline receptor subtype 1 (I1) and to a lesser extent lpha-2-adrenoreceptors in the RSV causing a reduction of sympathetic activity, reducing systemic vascular resistance and thus arterial blood pressure. Moreover, since alpha-2-adrenergic receptors are considered the primary molecular target that facilitates the most common side effects of sedation and dry mouth that are elicited by most centrally acting antihypertensives, moxonidine differs from these other centrally acting antihypertensives by demonstrating only low affinity for central alpha-2-adrenoceptors compared to the aforementioned I1-imidazoline receptors.
Market Place
